Learn More
Description
Rifamycin SV inhibits selective (E. coli, B. subtilis) bacterial DNA-dependent RNA polymerase by binding to the polymerase β-subunit, a mechanism similar to rifabutin. It acts as a selective cytochrome P450 3A4 inducer. It has limited oral absorption. It is active against Gram-positive bacteria and is moderately active against Gram-negative organisms.
- Used to study potential genes, such as rif15 and rif16, which may be involved in the conversion of rifamycin SV into rifamycin B
- Potential treatment for traveler’s diarrhea (TD), Clostridium difficile-associated disease (CDAD) and rheumatoid knee synovitis
- It is used in electron spin resonance studies
Specifications
Specifications
| CAS | 14897-39-3 |
| Molecular Formula | C37H47NNaO12 |
| MDL Number | MFCD09752825 |
| Quantity | 250 mg |
| Synonym | rifamycin sodium salt, rifamycin sodium usan, rifamycin sv sodium salt, rifocina tn, otofa tn |
| Solubility Information | Ethanol: soluble (50mg/mL) |
| InChI Key | YVOFSHPIJOYKSH-DITFEXNXSA-N |
| SMILES | [Na+].CO[C@H]1\C=C/O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O |
| IUPAC Name | sodium (7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1⁴,⁷.0⁵,²⁸]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate |
| Molecular Weight (g/mol) | 720.77 |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.